Close Menu

NEW YORK – An experimental small molecule MET tyrosine kinase inhibitor called savolitinib (AZD6094, HMPL-504, or volitinib under development from AstraZeneca) may be useful for treating patients with a subset of advanced papillary renal cell carcinoma (PRCC) kidney cancer that involves MET drivers, according to a new clinical study. The randomized Phase III clinical trial stopped enrollment early, though, due to new data from a comparator drug, sunitinib (Pfizer's Sutent).

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.


Join this webinar to learn how spatial resolution of gene expression in tumor tissue reveals new insights in biomarker discovery and therapeutic response. 


This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.


Non-small cell lung cancer (NSCLC) patients with ALK rearrangements are treated with tyrosine kinase inhibitors (TKIs), which often leads to prolonged overall survival. However, treatment resistance will almost inevitably occur, and the disease remains incurable.